Neoadjuvant S-1 and oxaliplatin plus bevacizumab therapy for high-risk locally advanced rectal cancer: A prospective multicenter phase II study.
Takuya MiuraHajime MorohashiYoshiyuki SakamotoTakuji KagiyaTatsuya HasebeYoshihito NakayamaHiromasa FujitaKenichi HakamadaPublished in: Annals of gastroenterological surgery (2023)
NAC yielded a clinically significant effect in about half of high-risk LARC patients. If NAC alone is ineffective, radiotherapy should be added, even if extended surgery is intended.
Keyphrases
- locally advanced
- rectal cancer
- phase ii study
- neoadjuvant chemotherapy
- squamous cell carcinoma
- radiation therapy
- end stage renal disease
- transcription factor
- ejection fraction
- chronic kidney disease
- minimally invasive
- peritoneal dialysis
- randomized controlled trial
- cross sectional
- clinical trial
- open label
- acute coronary syndrome
- surgical site infection
- patient reported